皮肤利什曼病的局部治疗的治疗进展：综述。
Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.
机构信息
Department of Pharmacy, Institute of Chemical and Pharmaceutical Sciences, Kohat University of Science and Technology, Kohat, Khyber Pakhtunkhwa, Pakistan.
Department of Zoology, Kohat University of Science and Technology, Kohat, Khyber Pakhtunkhwa, Pakistan.
出版信息
PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009099. doi: 10.1371/journal.pntd.0009099. eCollection 2021 Mar.
Abstract
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide specially in developing and underdeveloped countries. There are 2 major types of cutaneous leishmaniasis based on the causating species found in different regions of the world. These include New and Old World cutaneous leishmaniasis, which are self-healing, but if not treated, these may cause severe scars and many other complications like mucosal involvement. The conventional gold standard treatment for both types is mainly intralesional or parenteral administration of antimonial. Lately, a great deal of research has been done on development of topical treatment based on single agent or combination therapy. This review summarizes the current state of literature regarding therapeutic outcome of topical treatment against cutaneous leishmaniasis caused by different species in different regions.
摘要
皮肤利什曼病数十年来一直呈地方性流行。全世界报告了数百万例病例，特别是在发展中国家和不发达国家。根据世界不同地区发现的致病物种，有 2 种主要类型的皮肤利什曼病。这些包括新和旧世界皮肤利什曼病，它们是可以自行愈合的，但如果不治疗，这些疾病可能会导致严重的疤痕和许多其他并发症，如黏膜受累。这两种类型的传统金标准治疗主要是局部或静脉内给予锑剂。最近，人们对基于单一药物或联合疗法的局部治疗的开发进行了大量研究。这篇综述总结了有关不同地区不同物种引起的皮肤利什曼病的局部治疗疗效的文献现状。
相似文献
1
Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.皮肤利什曼病的局部治疗的治疗进展：综述。
PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009099. doi: 10.1371/journal.pntd.0009099. eCollection 2021 Mar.
2
Current treatment for cutaneous leishmaniasis: a review.皮肤利什曼病的当前治疗方法：综述
Am J Ther. 2009 Mar-Apr;16(2):178-82. doi: 10.1097/MJT.0b013e3181822e90.
3
Treatment of New World cutaneous and mucosal leishmaniases.新大陆皮肤利什曼病和黏膜利什曼病的治疗。
Clin Dermatol. 1996 Sep-Oct;14(5):519-22. doi: 10.1016/0738-081x(96)00048-x.
4
Successful treatment against American cutaneous leishmaniasis by intralesional infiltration of a generic antimonial compound-lidocaine combination. A follow up study.通过病灶内注射一种普通锑化合物-利多卡因组合成功治疗美洲皮肤利什曼病。一项随访研究。
Acta Trop. 2018 Sep;185:261-266. doi: 10.1016/j.actatropica.2018.06.001. Epub 2018 Jun 5.
5
Treatment of cutaneous leishmaniasis among travellers.旅行者皮肤利什曼病的治疗
J Antimicrob Chemother. 2004 Feb;53(2):158-66. doi: 10.1093/jac/dkh058. Epub 2004 Jan 16.
6
Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.旧世界利什曼原虫皮肤利什曼病对脂质体两性霉素 B 无反应，用局部咪喹莫特治疗。
Pediatr Infect Dis J. 2012 Jan;31(1):97-100. doi: 10.1097/INF.0b013e31822dfbf7.
7
Topical tamoxifen in the therapy of cutaneous leishmaniasis.局部使用他莫昔芬治疗皮肤利什曼病。
Parasitology. 2018 Apr;145(4):490-496. doi: 10.1017/S0031182017000130. Epub 2017 Mar 9.
8
[Management of cutaneous leishmaniasis in adults and children].[成人及儿童皮肤利什曼病的管理]
Med Trop (Mars). 2005 Nov;65(5):487-95.
9
Miltefosine Combined with Intralesional Pentamidine for Cutaneous Leishmaniasis in Bolivia.米替福新联合腔内喷他脒治疗玻利维亚皮肤利什曼病。
Am J Trop Med Hyg. 2018 Nov;99(5):1153-1155. doi: 10.4269/ajtmh.18-0183.
引用本文的文献
1
Flavonoids in the treatment of : a review of efficacy and mechanisms.黄酮类化合物在治疗中的应用：疗效与作用机制综述
Front Pharmacol. 2025 Aug 7;16:1642005. doi: 10.3389/fphar.2025.1642005. eCollection 2025.
2
Comparative Gut Proteome of from Leishmaniasis Endemic and Non-Endemic Areas of Amazon Reveals Differences in Microbiota and Proteins Related to Immunity and Gut Function.来自亚马逊利什曼病流行区和非流行区的比较肠道蛋白质组揭示了微生物群以及与免疫和肠道功能相关蛋白质的差异。
Microorganisms. 2025 Jun 4;13(6):1304. doi: 10.3390/microorganisms13061304.
3
Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action.用于皮肤利什曼病局部治疗的脂质纳米载体：作用机制洞察
ACS Omega. 2025 Jun 5;10(23):23873-23888. doi: 10.1021/acsomega.5c00046. eCollection 2025 Jun 17.
4
Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.全球旅行、移民、难民群体及人道主义危机背景下的皮肤利什曼病
Clin Pract. 2025 Apr 8;15(4):77. doi: 10.3390/clinpract15040077.
5
Mutual Role of Patients and the Healthcare System in the Control of Cutaneous Leishmaniasis.患者与医疗保健系统在皮肤利什曼病控制中的相互作用
Transbound Emerg Dis. 2023 Aug 26;2023:7814940. doi: 10.1155/2023/7814940. eCollection 2023.
6
Epidemiology and future risk estimates of cutaneous leishmaniasis in district Dera Ismail Khan, Pakistan: analysis of data from 2019-2022.巴基斯坦德拉伊斯梅尔汗地区皮肤利什曼病的流行病学及未来风险评估：2019 - 2022年数据分析
Afr Health Sci. 2024 Dec;24(4):51-64. doi: 10.4314/ahs.v24i4.8.
7
Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model.脱氢甲状腺原氨酸对皮肤利什曼病的作用：小鼠模型中的治疗结果
Mar Drugs. 2024 Dec 28;23(1):13. doi: 10.3390/md23010013.
8
A novel inhibitory strategy of using and killer toxins.一种使用杀伤毒素的新型抑制策略。
Future Microbiol. 2025 Feb;20(3):189-199. doi: 10.1080/17460913.2024.2443329. Epub 2024 Dec 20.
9
Therapeutic effect of topical tamoxifen in murine cutaneous leishmaniasis caused by .局部使用他莫昔芬对由……引起的小鼠皮肤利什曼病的治疗效果。 （原文中“caused by”后面内容缺失）
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0035824. doi: 10.1128/aac.00358-24. Epub 2024 Oct 24.
10
Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment.基于Sepigel的葡甲胺锑酸盐和两性霉素B治疗皮肤利什曼病的评估。
Pathogens. 2024 Aug 22;13(8):712. doi: 10.3390/pathogens13080712.
本文引用的文献
1
Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis.载纳米弹性脂质体的葡萄糖酸锑钠和酮康唑作为多药载体：一种治疗皮肤利什曼病的新方法。
Eur J Pharm Sci. 2020 Mar 30;145:105256. doi: 10.1016/j.ejps.2020.105256. Epub 2020 Feb 4.
2
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.近年来，两性霉素 B 递药策略在治疗利什曼病方面的进展。
Expert Opin Drug Deliv. 2019 Oct;16(10):1063-1079. doi: 10.1080/17425247.2019.1659243. Epub 2019 Aug 30.
3
Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment.载布比喹酮和多黏菌素 B 的纳米结构脂质载体用于利什曼病治疗的联合递药。
J Glob Antimicrob Resist. 2019 Sep;18:279-283. doi: 10.1016/j.jgar.2019.06.006. Epub 2019 Jun 13.
4
Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.开发含有米替福新的局部脂质体，用于治疗易感 BALB/c 小鼠中的利什曼原虫感染。
Acta Trop. 2019 Aug;196:142-149. doi: 10.1016/j.actatropica.2019.05.018. Epub 2019 May 16.
5
Topical paromomycin for New World cutaneous leishmaniasis.局部用巴龙霉素治疗新热带皮肤利什曼病。
PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253. doi: 10.1371/journal.pntd.0007253. eCollection 2019 May.
6
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.新型皮肤利什曼病实验模型中局部米替福新凝胶的抗利什曼原虫活性。
J Antimicrob Chemother. 2019 Jun 1;74(6):1634-1641. doi: 10.1093/jac/dkz049.
7
Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.局部应用 15%巴龙霉素-亲水性凝胶治疗玻利维亚巴西利什曼原虫皮肤利什曼病：一项随机、安慰剂对照试验。
Clin Infect Dis. 2019 Feb 15;68(5):844-849. doi: 10.1093/cid/ciy619.
8
Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.载纳米变形脂质体的葡萄糖酸锑钠用于治疗利什曼病的局部治疗：巨噬细胞作为靶细胞。
Drug Deliv. 2018 Nov;25(1):1595-1606. doi: 10.1080/10717544.2018.1494222.
9
A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.一项评估局部 3%两性霉素 B 乳膏（Anfoleish）治疗哥伦比亚无并发症皮肤利什曼病的安全性和疗效的 II 期研究。
PLoS Negl Trop Dis. 2018 Jul 25;12(7):e0006653. doi: 10.1371/journal.pntd.0006653. eCollection 2018 Jul.
10
Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases.布帕喹酮纳米结构脂质载体：开发一种用于治疗利什曼病的经济适用型给药系统。
Biomed Res Int. 2017;2017:9781603. doi: 10.1155/2017/9781603. Epub 2017 Feb 1.
Zotero 插件